CPA
ALXO icon

Capital Performance Advisors’s ALX Oncology ALXO Stock Holding History

Capital Performance Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$36 – 282
2024
Q3 		$36 Buy
+20
New +$74 ﹤0.01% 2825

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Capital Performance Advisors's ALXO Position: Q4 2024 in Review

Capital Performance Advisors sold out of ALX Oncology (ALXO) in Q4 2024, closing a stake of 20 shares — an estimated $36 sold.

Capital Performance Advisors first reported a position in ALXO in Q3 2024 and held it in 1 quarter. The position peaked at $36 in Q3 2024. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2024.

  • Capital Performance Advisors reported no remaining ALX Oncology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 20 ALX Oncology shares in Q4 2024, an estimated $36.
  • Capital Performance Advisors first reported a position in ALX Oncology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's ALX Oncology position peaked at $36 in Q3 2024.
  • 87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.